Theravance (THRX)

Add to Watchlists
Create an Alert
27.55 +0.90  +3.38% NASDAQ Apr 22, 8:00PM BATS Real time Currency in USD
View Full Chart
THRX Price Chart
View All Events

THRX Events

Date Type Description
May 06 Misc Q1 2014 Theravance, Inc. Earnings Conference Call
May 06 Earnings Q1 2014 Theravance, Inc. Earnings Results. Estimate: -0.53.
Apr 01 Misc Theravance Appoints Kevin Kwok, Head of Talent Acquisition and Strategy
Feb 06 Misc Theravance to Report Fourth Quarter and Full Year 2013 Conference Call
Feb 06 Earnings Theravance to Report Fourth Quarter and Full Year 2013 Financial Results. Estimate: -0.39.
Oct 24 Misc Theravance Third Quarter 2013 Financial Results Conference Call
Oct 24 Earnings Theravance to Report Third Quarter 2013 Financial Results on October 24, 2013. Estimate: -0.79.
Jul 25 Misc Theravance, Inc. Second Quarter Earnings Conference Call
Jul 25 Earnings Theravance to Report Second Quarter 2013 Financial Results on July 25, 2013. Estimate: -0.59.
Apr 25 Misc Theravance, Inc. First Quarter Earnings Conference Call
View All Performance Charts

THRX Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Theravance is down 13.81% over the last year vs S&P 500 Total Return up 23.42%, GlaxoSmithKline up 14.40%, and Alexion Pharmaceuticals up 72.58%.

Get Quote for

PDF Report for THRX

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download THRX Pro Report PDF

Portfolio Strategies Featuring THRX

Did Theravance make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

THRX Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELOVAIRTM, LAMA/LABA (‘719/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist (PµMA) program. The company was founded by P. Roy Vagelos, Mathai Mammen and George M. Whitesides in November 1996 and is headquartered in South San Francisco, California.

Recent Quotes

Symbol Price Chg Chg % Market Cap
THRX 27.55 +0.90 +3.38% 3.082B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.